The U.S. Food and Drug Administration has approved the first generic Robenacoxib tablet for managing postoperative pain and inflammation in cats. Sponsored by ZyVet Animal Health, the approval broadens access to effective feline pain relief while offering veterinarians and pet owners a more affordable treatment option.
The U.S. Food and Drug Administration has approved the first generic version of Robenacoxib tablets for use in cats, representing an important step forward in veterinary pharmaceutical availability. This approval enables veterinarians to prescribe a lower-cost alternative for controlling postoperative pain and inflammation in feline patients following surgical procedures.
Robenacoxib is a non-steroidal anti-inflammatory drug specifically formulated for cats and is commonly used after soft tissue and orthopedic surgeries. The newly approved generic tablet, sponsored by ZyVet Animal Health, has been determined to be therapeutically equivalent to the branded reference product already available in the market.
Key Highlights
-
FDA approval confirms that the generic Robenacoxib tablet meets the same safety, effectiveness, and quality standards as the reference drug
-
The medication is indicated for the control of postoperative pain and inflammation in cats following surgical procedures
-
The approval supports improved accessibility and affordability of essential veterinary pain management therapies
-
ZyVet Animal Health is the sponsor of the newly approved generic formulation
The availability of this generic option is expected to ease financial pressure on veterinary practices and pet owners while maintaining reliable clinical outcomes. The decision also reflects the FDA’s ongoing efforts to promote competition and expand access to approved generic animal medicines.
Sources: Reuters, U.S. Food and Drug Administration, ZyVet Animal Health